Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.

Literature DB >> 26033720

Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.

Janessa M Smith¹, Edina Avdic², Pranita D Tamma³, Long Zhang⁴, Karen C Carroll⁵, Sara E Cosgrove⁶.

Abstract

The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 26033720 PMCID： PMC4505236 DOI： 10.1128/AAC.00046-15

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.

Authors: David W Hecht
Journal: Clin Infect Dis Date: 2004-06-03 Impact factor: 9.079

2. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.

Authors: M H Nguyen; V L Yu; A J Morris; L McDermott; M W Wagener; L Harrell; D R Snydman
Journal: Clin Infect Dis Date: 2000-06-13 Impact factor: 9.079

3. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Authors: D R Snydman; N V Jacobus; L A McDermott; Y Golan; E J C Goldstein; L Harrell; S Jenkins; D Newton; C Pierson; J Rosenblatt; R Venezia; S L Gorbach; A M Queenan; D W Hecht
Journal: Anaerobe Date: 2011-06-02 Impact factor: 3.331

4. Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients.

Authors: Y M Chen; H C Lee; C M Chang; Y C Chuang; W C Ko
Journal: J Microbiol Immunol Infect Date: 2001-06 Impact factor: 4.399

5. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

Authors: D R Snydman; L McDermott; G J Cuchural; D W Hecht; P B Iannini; L J Harrell; S G Jenkins; J P O'Keefe; C L Pierson; J D Rihs; V L Yu; S M Finegold; S L Gorbach
Journal: Clin Infect Dis Date: 1996-12 Impact factor: 9.079

6. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

Authors: D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal: Clin Infect Dis Date: 2002-09-01 Impact factor: 9.079

7. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors: Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal: Antimicrob Agents Chemother Date: 2008-07-14 Impact factor: 5.191

Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.

1. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.

2. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.

3. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

4. Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients.

5. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

6. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

7. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

8. Clinical significance and outcome of anaerobic bacteremia.

9. Risk factors for mortality in patients with anaerobic bacteremia.

10. Reemergence of anaerobic bacteremia.

1. Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.

2. Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan.